Bimekizumab 4-year Maintenance of Responses in Week 16 Responders with Moderate to Severe Plaque Psoriasis: Results from the BE BRIGHT Open-label Extension Phase 3 Trial. J of Skin [Internet]. 2024 Nov. 18 [cited 2025 Oct. 19];8(6):s437. Available from: https://skin.dermsquared.com/skin/article/view/3114